Diffuse Large B-cell Lymphoma Recurrent Clinical Trials

10 clinical trials for Diffuse Large B-cell Lymphoma Recurrent across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL — RECRUITING · PHASE2
• CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma — RECRUITING · PHASE1
• A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL — RECRUITING · PHASE2
• R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma — WITHDRAWN · PHASE2
• Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL — OTHER · PHASE2
• Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — COMPLETED · PHASE2
• Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. — COMPLETED · PHASE2
• The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study — COMPLETED
• Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL — OTHER · PHASE1
• RICE-ibrutinib in Relapsed DLBCL — OTHER · PHASE2

Refine this search